Ironwood Pharmaceuticals, Inc. (IRWD)

Market Cap	591.90M +153.4%
Revenue (ttm)	296.15M -15.7%
Net Income	24.02M +2,629.2%
EPS	0.15 +2,583.0%
Shares Out	163.06M
PE Ratio	24.46
Forward PE	2.69
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,221,831
Open	3.600
Previous Close	3.600
Day's Range	3.510 - 3.650
52-Week Range	0.527 - 5.780
Beta	0.17
Analysts	Hold
Price Target	4.94 (+36.09%)
Earnings Date	May 6, 2026

About IRWD

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2010
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: IRWD
• Website: https://ironwoodpharma.com

Financial Performance

In 2025, Ironwood Pharmaceuticals's revenue was $296.15 million, a decrease of -15.72% compared to the previous year's $351.41 million. Earnings were $24.02 million, an increase of 2629.20%.

Analyst Summary

According to 5 analysts, the average rating for IRWD stock is "Hold." The 12-month stock price target is $4.94, which is an increase of 36.09% from the latest price.

Price Target

$4.94

(36.09% upside)

Analyst Consensus: Hold